Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Fernández Montes, Ana (Complexo Hospitalario Universitario de Ourense - CHUO)
Elez, Elena (Vall d'Hebron Institut d'Oncologia)
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia)
Martínez Lago, Nieves (Complejo Hospitalario Universitario de A Coruña)
González, P. (Hospital Álvaro Cunqueiro (Vigo))
Covela, M. (Hospital Universitario Lucus Augusti (Lugo))
De la Cámara, Juan (Hospital Universitario Arquitecto Marcide (Ferrol, Galícia))
Cousillas, Antía (Hospital Provincial de Pontevedra)
Méndez, J. C. (Centro Oncológico de Galicia)
Graña, B. (Complejo Hospitalario Universitario de A Coruña)
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies). Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test). Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Metastatic colorectal cancer ; Circulating tumor DNA ; Liquid biopsy ; RAS mutant ; EGFR inhibitors
Publicat a:	Clinical & translational oncology, Vol. 24 (january 2022) , p. 1209-1214, ISSN 1699-3055

DOI: 10.1007/s12094-021-02767-7
PMID: 34997474

6 p, 681.9 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats